Our Services
Medical Information
Helpful Resources
Published on: 10/26/2026
Vision changes reported with Wegovy (semaglutide) include blurred vision, temporary focusing difficulty linked to rapid blood sugar or weight shifts, worsening of existing diabetic retinopathy, and rare reports of sudden optic nerve damage known as NAION. Sudden vision loss, eye pain, double vision, or a surge of flashes and floaters are urgent red flags that warrant same-day medical care, while gradual blurring often warrants a prompt eye exam and a medication review. Timing matters too, since many reported changes surface within the first weeks or months of starting or increasing a dose, and several other factors can influence your risk, so see below to understand more.
Because vision symptoms can stem from the medication, an underlying eye or metabolic condition, or something unrelated entirely, a quick structured review of your symptoms can help you decide how fast to act and who to see. Take a free, instant, online symptom check to clarify what your specific symptoms may point to and get guidance on your next steps.
Last reviewed for medical accuracy: 10/22/2026
As Wegovy (semaglutide) gains popularity for weight management, some people have raised questions about potential Wegovy vision changes. This article reviews what’s known from clinical trials, case reports, and expert guidance—and offers practical steps for keeping your eyes healthy while on Wegovy.
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics a natural hormone that helps control appetite and blood sugar. While most side effects involve the digestive system (nausea, diarrhea, constipation), any medication that changes blood sugar or hydration status can sometimes affect vision.
Key points about Wegovy:
Though rare, some users have described:
Most of these reports have not risen to the level of a formal safety signal, but they’re worth knowing about—especially if you have risk factors for eye disease.
Rapid Blood Sugar Changes
Fluid Shifts and Dehydration
Existing Eye Conditions
Consider extra vigilance if you have any of the following:
If you’re in one of these groups, talk with your eye doctor before and during Wegovy treatment. A baseline eye exam can help catch small changes early.
Vision changes can be alarming—but not all require emergency care. Use this guide to decide when to reach out:
Urgent (Call 911 or go to the ER):
Prompt (Contact your doctor same day):
Routine (Mention at your next check-up):
If you’re ever unsure, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify what might be going on. It’s a quick way to get guidance before you make travel or appointment decisions.
Monitor Blood Sugar Carefully
Stay Hydrated
Schedule Regular Eye Exams
Be Alert to Symptoms
Communicate with Your Provider
Wegovy offers significant benefits for weight loss, which in turn can improve blood pressure, cholesterol, and overall metabolic health. For many, these gains outweigh the low risk of vision changes. Still, being proactive helps you enjoy the full benefits while minimizing potential downsides.
Remember:
In rare cases, your doctor might advise stopping or pausing Wegovy, such as:
Any decision about stopping a prescription should involve a thorough discussion of risks and benefits.
Vision changes on Wegovy are uncommon but worth monitoring—especially if you have diabetes or a history of eye disease. By combining regular eye check-ups, careful blood sugar management, and good hydration, you can reduce the chance of problems and catch any issues early.
If you notice any worrying symptoms or simply want personalized guidance, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. And always speak to a healthcare professional about anything that could be life threatening or serious. Your vision is too important to leave to chance.
(References)
* Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab. 2017 Sep;19(9):1242-1251. doi: 10.1111/dom.12932. Epub 2017 May 5. PMID: 28266779; PMCID: PMC5573908.
* Kalra S, Arora S, Kapoor N. Classification of Non-Insulin Glucose Lowering Drugs. J Pak Med Assoc. 2022 Jan;72(1):181-182. doi: 10.47391/JPMA.22-003. PMID: 35099465.
* Niu S, Chen S, Chen X, Ren Q, Yue L, Pan X, Zhao H, Li Z, Chen X. Semaglutide ameliorates metabolism and hepatic outcomes in an NAFLD mouse model. Front Endocrinol (Lausanne). 2022;13:1046130. doi: 10.3389/fendo.2022.1046130. Epub 2022 Dec 9. PMID: 36568109; PMCID: PMC9780435.
* Cigrovski Berkovic M, Strollo F. Semaglutide-eye-catching results. World J Diabetes. 2023 Apr 15;14(4):424-434. doi: 10.4239/wjd.v14.i4.424. PMID: 37122431; PMCID: PMC10130900.
* Amini A, Hamann S, Larsen M. Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association. Acta Ophthalmol. 2025 Sep;103(6):615-621. doi: 10.1111/aos.17473. Epub 2025 Mar 8. PMID: 40055951; PMCID: PMC12340176.
* Thomsen RW, Mailhac A, Løhde JB, Pottegård A. Real-world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer GLP-1RA-based weight-loss therapies. Diabetes Obes Metab. 2025 Apr;27 Suppl 2(Suppl 2):66-88. doi: 10.1111/dom.16364. Epub 2025 Apr 8. PMID: 40196933; PMCID: PMC12000858.
* Wang L, Volkow ND, Kaelber DC, Xu R. Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. JAMA Netw Open. 2025 Aug 1;8(8):e2526327. doi: 10.1001/jamanetworkopen.2025.26327. Epub 2025 Aug 1. PMID: 40788646; PMCID: PMC12340659.
* Natividade GR, Spiazzi BF, Baumgarten MW, Bassotto C, Pereira AA, Fraga BL, Scalco BG, Mattes NR, Lavinsky D, Kramer CK, Gerchman F. Ocular Adverse Events With Semaglutide: A Systematic Review and Meta-Analysis. JAMA Ophthalmol. 2025 Sep 1;143(9):759-768. doi: 10.1001/jamaophthalmol.2025.2489. PMID: 40810985; PMCID: PMC12355393.
* Therapeutic Benefit or Ocular Risk? Semaglutide and Non-Arteritic Anterior Ischemic Optic Neuropathy [RETRACTED]. Retina. 2025 Oct 22. doi: 10.1097/IAE.0000000000004709. Epub 2025 Oct 22. PMID: 41144820.
* Saleem NUA, Khan M, Tague C, Akilimali A. The unseen risk of Ozempic: NAION and vision damage. Ann Med Surg (Lond). 2025 Dec;87(12):7898-7899. doi: 10.1097/MS9.0000000000004149. Epub 2025 Oct 20. PMID: 41377330; PMCID: PMC12688804.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.